SRF and breast carcinoma: Our present study demonstrates a distinct regulatory role of miR-564 in breast cancer progression by direct targeting of a network of genes, namely AKT2, GNA12, GYS1 and SRF that leads to simultaneous inhibition of PI3K and MAPK pathways.